Latigo Biotherapeutics Inc.

LTGO

NASDAQHealthcareMedical - Pharmaceuticals

在 GoAI 中打开

前收盘价

US$22.55

−US$1.38 · -5.77%

9月18日 16:00 ET

公司概况

公司网站

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

行业: Medical - Pharmaceuticals
部门: Healthcare
总部: US
首席执行官: Nima Farzan
上市以来: 2026年8月7日
雇员: 59

市场位置

日内区间

当前US$22.55

US$22.21US$24.50

52周区间

当前US$22.55

US$17.22US$25.93

开盘价: US$24.18
前收盘价: US$23.93
成交量: 148.82万; 4.03× 平均值
平均成交量: 36.96万; 日均成交量
市值: 13.56亿 USD
贝塔: 0; 市场参考 1
50天平均值: US$21.7727; 高于平均水平+3.57%
200天平均值: US$21.7727; 高于平均水平+3.57%

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$52.25

上涨空间 131.71%

过去 12 个月12个月预测最高：US$73.00平均的：US$52.25最低：US$36.00

LTGO 消息

defenseworld.net2026年9月9日

Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)

Latigo Biotherapeutics' (NASDAQ: LTGO - Get Free Report) quiet period will expire on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its public offering on August 7th. The total size of…

阅读源码

globenewswire.com2026年9月3日

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund…

阅读源码

247wallst.com2026年8月13日

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.

阅读源码

defenseworld.net2026年8月11日

Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) Director James Tananbaum bought 140,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an…

阅读源码

defenseworld.net2026年8月11日

Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares…

阅读源码

businesswire.com2026年7月29日

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive…

阅读源码